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Introduction
Tumor progression to the malignant phenotype is
greatly dependent on the permissive action of the
microenviroment. From angiogenesis to inflamma-
tion to metastasis, the interactions of cells with their
microenviroment provide many of the essential fac-
tors. One critical factor regulated by the tumor
microenviroment is the production of specific prote-
olytic enzymes and protease inhibitors capable of
altering the immediate pericellular milieu [3]. Mem-
brane type matrix metalloproteinases (MT-MMPs)
play a central role in the locomotion of many cell
types. MT1-MMP is also known as MMP-14 and is
the most common and thoroughly studied member of
the MT-MMP subfamily. It is widely expressed in
tumors and is frequently associated with enhanced
tumorigenicity of many cancer types [4].
At present, little is known about how MT1-
MMP/MMP-14 expression is regulated on the plasma
membrane. The shedding of membrane-tethered
MT1-MMP/MMP-14 from the cell surface, however,
offers a concrete mechanism how membrane-bound
MMP activity at the cell surface could be regulated.
MT-MMPs have a unique regulatory mechanism in
which an active enzyme undergoes a series of pro-
cessing steps, either autocatalytic or mediated by
other proteases, that regulate the activity and nature
of the enzyme species at the cell surface and at the
pericellular space [2]. The processing of active MT1-
MMP (57 kDa) is mostly an autocatalytic intermole-
cular event that results in the generation of an inac-
tive membrane-tethered form of 44 kDa and in the
shedding of the catalytic domain.
However, data on circulating MT1-MMP/MMP-14
in patients with breast cancer are lacking. Therefore we
attempted to determine soluble MT1-MMP/MMP-14
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levels in sera of women without clinically apparent
metastases.
Materials and methods
Patients. A total of 18 patients (of which four T1b, one T1c and thir-
teen T2) diagnosed with ductal breast carcinoma but without clini-
cally apparent metastases were involved in this study. 11 healthy
controls served as controls. The mean (±SD) age of patients in the
study and control groups was similar (54.06±13.02 and 53.56±14.95
years old, respectively).
Serum samples. Sera were obtained prior to surgery according to
the ethical standards, with informed consent obtained from every
patient. Patients had not received any preoperative chemo- or hor-
monal therapy. Clinicopathological characteristics of patients are
shown in Table 1.
For all patients, the histological diagnosis and the stage of
cancer were established by assessment of paraffin sections. His-
tological grading was performed according to Bloom and
Richardson [1]. MT1-MMP/MMP-14 levels were measured by
the activity enzyme-linked immunosrobent assay (Amersham
Pharmacia Biotech). It uses the preform of a detection enzyme,
which is activated by the respective MMP and represents the con-
centrations of the soluble/active form of the enzyme. The assays'
range of detection is 1-32 ng/ml. All measurements were made in
duplicate and averaged.
Ethical issues. The study was approved by the Ethics Committee
of the Medical University of Bialystok.
Statistical analysis. Student t-test accepting p value less than 0.05
as significant was used for the statistical analysis and assumptions
were checked by Kolmogorov test. The analysis was performed by
the use of SAS STAT package and Graph Prism. 
Results
We found that the mean (±SD) MT1-MMP/MMP-14
concentrations in serum of patients with ductal breast
cancer was 16.91±5.87 ng/ml, in comparison with
8.55±1.66 ng/ml in the control group (p<0.0001), a
statistically significant difference (Fig. 1). No differ-
ences in MT1-MMP/MMP-14 levels were found
between patients with (N1, N2) and without lymph
node involvement, between tumor grade (2, 3) or size
(1, 2). 
Discussion
Invasion and metastasis require the disruption of sev-
eral collagen-endowed tissue barriers, key among
which is the basement membrane that lines vascular
endothelial cells and constitutes a continuous physical
obstacle to tumor metastasis. MMPs have long been
associated with malignancy [5]. The concentrations of
MT1-MMP/MMP-14 in serum represent the levels of
active i.e. "shedded" protein. The shedding, by means
of overactivity of some types of proteolytic enzymes,
including plasmin and other MMPs, may also include
release of the entire extracellular extension of MT1-
MMP/MMP-14 comprising both the catalytic domain
and the C-terminal domain also known as the hemo-
pexin-like domain (HLD). While this process would
terminate activity on the plasma membrane independ-
ently of exogenous inhibitors, the shed catalytic
domain may contribute to pericellular proteolysis. 
It seems likely that increased serum concentrations
of MT1-MMP/MMP-14 in breast cancer patients may
result from accentuated shedding. A feasible explana-
tion is that pro-MT1-MMP/MMP-14 is transported
from intracellular compartments to the plasma mem-
brane, then becomes activated by plasmin extracellu-
larly to exert its proteolytic activity. Since overall
activity of plasmin in breast cancer patients is
increased it is possible that plasmin formation in the
tumor might be a contributory factor [6].
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Fig. 1 MT1-MMP/MMP-14 serum concentrations in ductal breast
cancer patients and controls.
Table. 1. Clinicopathological characteristics of breast cancer
patients.
It is difficult to speculate whether activity of the
enzyme proceeds or follows the metastasis formation
since in our study group half (n=9) of the patients had
histologically confirmed lymph node involvement. It
is plausible that increased activity of MT1-
MMP/MMP-14 might be involved in the enhanced
invasiveness at early steps and contribute to subse-
quent progression of the disease.
In summary, the increased levels of soluble MT1-
1/MMP-14 in the serum of breast cancer patients may
have implications in the pathogenesis of the disease.
Further studies are, however, required to delineate the
precise role of soluble MT1-1/MMP-14 in the biology
of breast cancer.
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